Alfa Biomed India Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Alfa Biomed India Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $51.1K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Alfa Biomed India Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $51.1K Trade | TransData Nexus

Alfa Biomed India Private Limited

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $51.1K Total Trade · DGFT Verified

Alfa Biomed India Private Limited is an Indian pharmaceutical exporter with a total trade value of $51.1K across 2 products in 2 therapeutic categories. Based on 35 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Pyrantel ($38.7K), Biotin ($12.4K), .

Alfa Biomed India Private Limited — Export Portfolio & Destination Treemap

Alfa Biomed India Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Alfa Biomed India Private Limited? — Company Overview & Market Position

Alfa Biomed India Private Limited, incorporated on February 10, 2016, is a private limited company based in Pune, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U74999PN2016FTC158316. As of the latest available data, Alfa Biomed India has an authorized capital of ₹68.10 crore and a paid-up capital of ₹27.84 crore. The company is unlisted and operates in the pharmaceutical sector, focusing on the manufacturing of finished pharmaceutical formulations.

The registered office is located at Gat No. 67 and 68, Ahirwade, Naigaon, Old Mumbai-Pune Highway, Village Maval, Pune, Maharashtra, 412106. The company employs approximately 174 professionals as of September 2, 2025.

What Does Alfa Biomed India Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Pyrantel$38.7K 2Biotin$12.4K

Product Portfolio — Top 2 by Export Value

Alfa Biomed India Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Pyrantel	Antimalarial & Antiparasitic	$38.7K	27	1.2%	11
2	Biotin	Vitamins & Supplements	$12.4K	8	0.8%	6

Alfa Biomed India Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $51.1K. The top category is Antimalarial & Antiparasitic (75.7% of portfolio), followed by Vitamins & Supplements (24.3%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Alfa Biomed India Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Alfa Biomed India Private Limited operates manufacturing facilities in Pune, Maharashtra. The plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding production capacities and specialized manufacturing capabilities are not publicly disclosed.

3Key Leadership

The leadership team of Alfa Biomed India Private Limited includes:

Aniket Bhalchandra Kulkarni – Additional Director, appointed on December 23, 2024.
Kiran Sukhdeo Malekar – Director, appointed on January 7, 2021.
Anushka Abhijit Bora – Additional Director, appointed on December 23, 2024.
Dinesh Chandak – Director, appointed on August 23, 2021.
Krishna Abhijit Bora – Additional Director, appointed on December 23, 2024.
Sahadot Ali Mir – Additional Director, appointed on July 23, 2025.

These appointments reflect the company's commitment to strengthening its leadership team to drive growth and operational excellence.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Alfa Biomed India Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Alfa Biomed India Private Limited's export activities, as per TransData Nexus proprietary trade data, include shipments totaling $51,000 USD across 35 transactions. The company's product portfolio comprises two products: Pyrantel and Biotin, exported to various international markets. However, specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available. The company's focus on finished pharmaceutical formulations suggests adherence to international quality standards, which is essential for market entry in these regulated regions.

2Emerging Markets

Alfa Biomed India Private Limited's export data indicates a concentration in the Antimalarial & Antiparasitic therapeutic category, accounting for 75.7% of total exports. This focus aligns with the company's potential strategic interest in emerging markets, particularly in regions like Africa and Southeast Asia, where such therapeutic products are in demand. While specific information on WHO prequalification or market penetration in these regions is not available, the company's product portfolio positions it to capitalize on opportunities in these emerging markets.

3Geographic Strategy

Alfa Biomed India Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Alfa Biomed India Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. Given the company's focus on finished pharmaceutical formulations, obtaining FDA approvals would be crucial for market access in the United States. The absence of publicly available data suggests that the company may not yet have established a presence in the U.S. market or is in the early stages of pursuing FDA approvals.

2WHO & EU GMP

There is no publicly available information confirming whether Alfa Biomed India Private Limited holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. Such certifications are essential for market access in various international markets. The company's focus on finished pharmaceutical formulations suggests that obtaining these certifications would be a strategic priority to enhance its global competitiveness.

3CDSCO & Indian Regulatory

Alfa Biomed India Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Alfa Biomed India Private Limited operates in the competitive pharmaceutical manufacturing sector, focusing on finished pharmaceutical formulations. While specific competitors in overlapping categories are not identified, the company's export data indicates a concentration in the Antimalarial & Antiparasitic therapeutic category. This suggests that the company faces competition from other manufacturers specializing in similar therapeutic areas. A detailed market share comparison and head-to-head analysis would require access to proprietary market research data.

2Key Differentiators

Alfa Biomed India Private Limited's focus on finished pharmaceutical formulations, particularly in the Antimalarial & Antiparasitic category, positions it to address specific therapeutic needs. The company's export activities indicate a commitment to international markets, reflecting a strategic approach to global expansion. However, the lack of product diversification and limited publicly available information on regulatory certifications may impact its competitive positioning.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Alfa Biomed India Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Alfa Biomed India Private Limited's export data indicates a total export value of $51,000 USD across 35 shipments, with a portfolio concentration of 100% in its top five products. This suggests a focused approach to its product offerings. The company's compliance with Indian regulatory standards is implied by its active status and operations in the pharmaceutical manufacturing sector. However, the lack of publicly available information on international certifications and regulatory approvals may impact its reliability as a supplier in global markets.

2Certifications to Verify

Importers should verify the following certifications before engaging with Alfa Biomed India Private Limited:

FDA Approval: Confirm that the company's products are approved by the U.S. Food and Drug Administration (FDA) for sale in the United States. Verification can be done through the FDA's official website or by contacting the company directly.

WHO-GMP Certification: Ensure that the company holds Good Manufacturing Practice (GMP) certification from the World Health Organization (WHO). This can be verified by checking the WHO's official list of prequalified manufacturers or by requesting certification details from the company.

Frequently Asked Questions — Alfa Biomed India Private Limited

How many pharmaceutical products does Alfa Biomed India Private Limited export from India?

Alfa Biomed India Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Pyrantel ($38.7K), Biotin ($12.4K). Total export value is $51.1K.

What is Alfa Biomed India Private Limited's total pharmaceutical export value?

Alfa Biomed India Private Limited's total pharmaceutical export value is $51.1K, based on 35 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Alfa Biomed India Private Limited cover?

Alfa Biomed India Private Limited exports across 2 therapeutic categories. The largest are Antimalarial & Antiparasitic (75.7%, 1 products), Vitamins & Supplements (24.3%, 1 products).

Get Full Alfa Biomed India Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.